NCT07068841View on ClinicalTrials.gov

Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 18, 2025

Primary Completion Date

July 15, 2025

Study Completion Date

August 30, 2025

Conditions
Pharmacokinetic ProfilesY-3 for InjectionDrug-drug InteractionRepaglinide TabletsWarfarin Sodium TabletsOmeprazole Enteric-coated CapsulesSafty
Interventions
DRUG

sequentially single use of repaglinide, warfarin and omeprazole or combined with Y-3

"Take repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules without Y-3.~Take repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules sequentially during the use of Y-3."

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Bengbu Medical College, Bengbu

Sponsors
All Listed Sponsors
lead

Neurodawn Pharmaceutical Co., Ltd.

INDUSTRY